Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 2/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21029145 | 0.91 | AAK1 (0.58) | AAK1SLC7A5PTPN1ITGA4ITGB7 | |
| SCHEMBL18511387 | 0.91 | AAK1 (0.61) | AAK1SLC7A5PTPN1ITGA4ITGB7 | |
| SCHEMBL3750181 | 0.89 | AAK1 (0.58) | AAK1SLC7A5PTPN1ITGA4ITGB7 | |
| SCHEMBL3750184 | 0.89 | AAK1 (0.58) | AAK1SLC7A5PTPN1ITGA4ITGB7 | |
| SCHEMBL18256471 | 0.86 | AAK1 (0.57) | AAK1SLC7A5PTPN1ITGA4ITGB7 | |
| SCHEMBL19088485 | 0.86 | AAK1 (0.57) | AAK1SLC7A5PTPN1ITGA4ITGB7 | |
| SCHEMBL30191506 | 0.86 | AAK1 (0.57) | AAK1SLC7A5PTPN1ITGA4ITGB7 | |
| SCHEMBL18511393 | 0.85 | AAK1 (0.65) | AAK1SLC7A5ITGA4ITGB7CTSD | |
| SCHEMBL25318449 | 0.84 | AAK1 (0.61) | AAK1SLC7A5ITGA4ITGB7CTSS | |
| SCHEMBL30949483 | 0.84 | AAK1 (0.62) | AAK1SLC7A5ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301286-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301286-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | AAK1 956/4885SLC7A5 2250/4885PTPN1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.